Investors Shift to High Dividend Stocks Amid Market Volatility
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 11 2026
0mins
Source: CNBC
- Increased Appeal of Dividend Stocks: In Q1 2026, nearly $22 billion flowed into dividend exchange-traded funds, marking the highest inflow since Q2 2022, indicating a trend of investors seeking relative safety amid market volatility.
- Uneven Market Performance: While the S&P 500 hit a new high on Monday, the market has been rocky this year due to factors like the Iran war, oil prices, and AI disruptions, leading to heightened demand for dividend stocks among investors.
- Analyst-Recommended Stocks: Stocks in the iShares Core High Dividend ETF have received buy or overweight ratings from over 55% of analysts, with expected price targets showing at least 15% upside, highlighting strong investment potential.
- Individual Stock Performance Analysis: For instance, AbbVie boasts a 3.4% dividend yield with 74% of analysts rating it a buy, while PNC Financial Services and PPL also show promising growth prospects with dividend yields of 3.1%, attracting investor interest.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ABBV?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ABBV
Wall Street analysts forecast ABBV stock price to rise
18 Analyst Rating
12 Buy
6 Hold
0 Sell
Moderate Buy
Current: 217.720
Low
223.00
Averages
252.00
High
289.00
Current: 217.720
Low
223.00
Averages
252.00
High
289.00
About ABBV
AbbVie Inc. is a global, diversified, research-based biopharmaceutical company. It is engaged in research and development, manufacturing, commercialization and sale of medicines and therapies. Its product portfolio includes Immunology, Oncology, Aesthetics, Neuroscience, Eye Care and Other Key Products. Immunology products include rheumatology, dermatology and gastroenterology. Oncology products include Imbruvica, Venclexta/Venclyxto, Elahere and Epkinly. The aesthetics portfolio consists of facial injectables, plastics and regenerative medicine, body contouring, and skincare products. Its Neuroscience products include Botox Therapeutic, Vraylar, Duopa and Duodopa, Ubrelvy, and Qulipta. Duodopa is a levodopa-carbidopa intestinal gel for the treatment of Parkinson's disease. Eye care products include Ozurdex, Lumigan/Ganfort, Alphagan/Combigan, Restasis, and other eye care. Other key products include Mavyret/Maviret, Creon, and Linzess/Constella.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Investment Comparison: AbbVie vs. Pfizer
- AbbVie's Financial Performance: In FY 2025, AbbVie reported revenue of approximately $61.2 billion, an 8.6% increase year-over-year, with a net income of about $4.2 billion and a net margin of 6.9%, indicating successful integration of new products despite customer concentration risks.
- Pfizer's Market Position: Pfizer generated nearly $62.6 billion in revenue for FY 2025, a slight decline of 1.6% from the previous year, yet achieved a net income close to $7.8 billion with a net margin of 12.4%, demonstrating effective cost management amid patent expiration challenges.
- Risk Overview: AbbVie faces significant revenue concentration with 42% of its income reliant on two major products, contending with competition from biosimilars and pricing pressures, while Pfizer must navigate patent expirations and high R&D costs, highlighting their strategic differences.
- Valuation Comparison: AbbVie has a forward P/E ratio of 14.7x compared to Pfizer's 8.7x, indicating that Pfizer appears more attractive in terms of valuation, although AbbVie shows stronger growth prospects and business stability.
See More
Comparative Investment Analysis of AbbVie and Pfizer
- Revenue Growth Comparison: AbbVie reported approximately $61.2 billion in revenue for FY 2025, reflecting an 8.6% increase, showcasing its robust pipeline in immunology and oncology despite facing patent cliffs.
- Profit Performance: Pfizer generated nearly $62.6 billion in revenue during the same fiscal year, a slight decline of 1.6% from the previous year, yet net income was close to $7.8 billion, yielding a net margin of 12.4%, indicating effective cost management.
- Financial Health Status: AbbVie's debt-to-equity ratio stands at -21.1x, indicating total liabilities exceed shareholder equity, while Pfizer's ratio is approximately 0.8x, demonstrating stronger financial leverage and short-term solvency.
- Market Competition and Risks: AbbVie relies on two major products for 42% of its revenue, facing competition from biosimilars, while Pfizer must manage revenue declines due to multiple patent expirations, requiring investors to weigh each company's growth potential against stability.
See More
Regulatory Approvals and Collaborations in Biotech Sector
- FDA Approval for AZN: AstraZeneca (AZN) secured FDA approval for the IMFINZI + BCG combination in high-risk non-muscle-invasive bladder cancer, supported by Phase 3 POTOMAC data showing a 32% reduction in recurrence or death, enhancing its competitive edge in oncology.
- JNJ TREMFYA Label Expansion: Johnson & Johnson (JNJ) received FDA approval to add structural joint-damage inhibition data to the TREMFYA label for active psoriatic arthritis, confirming its unique position in first-line treatment with no new safety signals, reinforcing its market leadership.
- LINZESS Approved for Children: Ironwood Pharmaceuticals (IRWD) gained FDA approval for LINZESS to treat functional constipation in children aged 2-5, based on a 12-week Phase 3 trial showing significant improvement in spontaneous bowel movements, expanding its pediatric market influence.
- AbbVie's DECNUPAZ Approval: AbbVie (ABBV) received FDA approval for DECNUPAZ to treat ultra-rare blood cancer BPDCN, supported by Phase 1 data showing a 69.7% composite complete response rate and a median duration of 9.7 months, marking a significant innovation in hematologic oncology.
See More
AbbVie Receives EU Approval for Expanded VENCLYXTO Indications
- Indication Expansion: AbbVie announced that the European Commission has approved an expanded label for VENCLYXTO to include its use in combination with acalabrutinib and ibrutinib for previously untreated chronic lymphocytic leukemia patients, enhancing its market competitiveness.
- Clinical Trial Support: The efficacy of VENCLYXTO in combination with acalabrutinib is supported by data from the Phase 3 AMPLIFY trial, which demonstrated a 35% reduction in the risk of disease progression or death compared to chemoimmunotherapy, showcasing significant clinical advantages.
- Survival Improvement: The combination of VENCLYXTO with ibrutinib is also backed by data from the Phase 3 GLOW and Phase 2 CAPTIVATE trials, which indicated clinically meaningful improvements in progression-free survival and overall survival at a 64-month follow-up.
- Market Impact: This authorization extends to all EU member states, as well as Iceland, Norway, and Liechtenstein, which is expected to drive ABBV's sales growth in the European market and further solidify its leadership position in blood cancer treatment.
See More
European Commission Approves Expanded Indication for VENCLYXTO
- Indication Expansion: The European Commission has approved the use of VENCLYXTO in combination with acalabrutinib (with or without obinutuzumab) and ibrutinib for adult patients with previously untreated chronic lymphocytic leukemia (CLL), significantly broadening its application in first-line treatment.
- Clinical Trial Support: The combination of VENCLYXTO and acalabrutinib was shown to be superior to chemoimmunotherapy in the Phase 3 AMPLIFY trial, reducing the risk of disease progression or death by 35%, thus providing patients with a more effective treatment option.
- Patient Benefits: The introduction of these new combination regimens not only offers chemotherapy-free fixed-duration options but also has the potential for treatment-free intervals, significantly improving patients' quality of life and reducing treatment burdens.
- Market Impact: This approval allows VENCLYXTO to be available across all EU member states, as well as Iceland, Norway, and Liechtenstein, which is expected to drive AbbVie's sales growth in the European market and further solidify its leadership in the blood cancer treatment sector.
See More
AbbVie Expands VENCLYXTO Indication for CLL Treatment
- Indication Expansion: The European Commission has authorized the use of VENCLYXTO in combination with acalabrutinib (with optional obinutuzumab) and ibrutinib for adult patients with previously untreated chronic lymphocytic leukemia (CLL), further solidifying AbbVie's leadership in hematologic cancer treatment.
- Clinical Trial Support: The combination of VENCLYXTO and acalabrutinib demonstrated superior efficacy over chemoimmunotherapy in the Phase 3 AMPLIFY trial, reducing the risk of disease progression or death by 35%, providing patients with a more effective treatment option.
- Patient Benefits: The new therapy's fixed-duration and chemotherapy-free nature offers the potential for treatment-free intervals, significantly improving patients' quality of life and meeting the evolving needs of patients and healthcare providers for flexible treatment options.
- Market Potential: With VENCLYXTO approved in over 80 countries, AbbVie enhances its competitive edge in the global market through this indication expansion, which is expected to drive future revenue growth for the company.
See More
Investment Comparison: AbbVie vs. Pfizer
- AbbVie's Financial Performance: In FY 2025, AbbVie reported revenue of approximately $61.2 billion, an 8.6% increase year-over-year, with a net income of about $4.2 billion and a net margin of 6.9%, indicating successful integration of new products despite customer concentration risks.
- Pfizer's Market Position: Pfizer generated nearly $62.6 billion in revenue for FY 2025, a slight decline of 1.6% from the previous year, yet achieved a net income close to $7.8 billion with a net margin of 12.4%, demonstrating effective cost management amid patent expiration challenges.
- Risk Overview: AbbVie faces significant revenue concentration with 42% of its income reliant on two major products, contending with competition from biosimilars and pricing pressures, while Pfizer must navigate patent expirations and high R&D costs, highlighting their strategic differences.
- Valuation Comparison: AbbVie has a forward P/E ratio of 14.7x compared to Pfizer's 8.7x, indicating that Pfizer appears more attractive in terms of valuation, although AbbVie shows stronger growth prospects and business stability.
See More
Comparative Investment Analysis of AbbVie and Pfizer
- Revenue Growth Comparison: AbbVie reported approximately $61.2 billion in revenue for FY 2025, reflecting an 8.6% increase, showcasing its robust pipeline in immunology and oncology despite facing patent cliffs.
- Profit Performance: Pfizer generated nearly $62.6 billion in revenue during the same fiscal year, a slight decline of 1.6% from the previous year, yet net income was close to $7.8 billion, yielding a net margin of 12.4%, indicating effective cost management.
- Financial Health Status: AbbVie's debt-to-equity ratio stands at -21.1x, indicating total liabilities exceed shareholder equity, while Pfizer's ratio is approximately 0.8x, demonstrating stronger financial leverage and short-term solvency.
- Market Competition and Risks: AbbVie relies on two major products for 42% of its revenue, facing competition from biosimilars, while Pfizer must manage revenue declines due to multiple patent expirations, requiring investors to weigh each company's growth potential against stability.
See More
Regulatory Approvals and Collaborations in Biotech Sector
- FDA Approval for AZN: AstraZeneca (AZN) secured FDA approval for the IMFINZI + BCG combination in high-risk non-muscle-invasive bladder cancer, supported by Phase 3 POTOMAC data showing a 32% reduction in recurrence or death, enhancing its competitive edge in oncology.
- JNJ TREMFYA Label Expansion: Johnson & Johnson (JNJ) received FDA approval to add structural joint-damage inhibition data to the TREMFYA label for active psoriatic arthritis, confirming its unique position in first-line treatment with no new safety signals, reinforcing its market leadership.
- LINZESS Approved for Children: Ironwood Pharmaceuticals (IRWD) gained FDA approval for LINZESS to treat functional constipation in children aged 2-5, based on a 12-week Phase 3 trial showing significant improvement in spontaneous bowel movements, expanding its pediatric market influence.
- AbbVie's DECNUPAZ Approval: AbbVie (ABBV) received FDA approval for DECNUPAZ to treat ultra-rare blood cancer BPDCN, supported by Phase 1 data showing a 69.7% composite complete response rate and a median duration of 9.7 months, marking a significant innovation in hematologic oncology.
See More
AbbVie Receives EU Approval for Expanded VENCLYXTO Indications
- Indication Expansion: AbbVie announced that the European Commission has approved an expanded label for VENCLYXTO to include its use in combination with acalabrutinib and ibrutinib for previously untreated chronic lymphocytic leukemia patients, enhancing its market competitiveness.
- Clinical Trial Support: The efficacy of VENCLYXTO in combination with acalabrutinib is supported by data from the Phase 3 AMPLIFY trial, which demonstrated a 35% reduction in the risk of disease progression or death compared to chemoimmunotherapy, showcasing significant clinical advantages.
- Survival Improvement: The combination of VENCLYXTO with ibrutinib is also backed by data from the Phase 3 GLOW and Phase 2 CAPTIVATE trials, which indicated clinically meaningful improvements in progression-free survival and overall survival at a 64-month follow-up.
- Market Impact: This authorization extends to all EU member states, as well as Iceland, Norway, and Liechtenstein, which is expected to drive ABBV's sales growth in the European market and further solidify its leadership position in blood cancer treatment.
See More
European Commission Approves Expanded Indication for VENCLYXTO
- Indication Expansion: The European Commission has approved the use of VENCLYXTO in combination with acalabrutinib (with or without obinutuzumab) and ibrutinib for adult patients with previously untreated chronic lymphocytic leukemia (CLL), significantly broadening its application in first-line treatment.
- Clinical Trial Support: The combination of VENCLYXTO and acalabrutinib was shown to be superior to chemoimmunotherapy in the Phase 3 AMPLIFY trial, reducing the risk of disease progression or death by 35%, thus providing patients with a more effective treatment option.
- Patient Benefits: The introduction of these new combination regimens not only offers chemotherapy-free fixed-duration options but also has the potential for treatment-free intervals, significantly improving patients' quality of life and reducing treatment burdens.
- Market Impact: This approval allows VENCLYXTO to be available across all EU member states, as well as Iceland, Norway, and Liechtenstein, which is expected to drive AbbVie's sales growth in the European market and further solidify its leadership in the blood cancer treatment sector.
See More
AbbVie Expands VENCLYXTO Indication for CLL Treatment
- Indication Expansion: The European Commission has authorized the use of VENCLYXTO in combination with acalabrutinib (with optional obinutuzumab) and ibrutinib for adult patients with previously untreated chronic lymphocytic leukemia (CLL), further solidifying AbbVie's leadership in hematologic cancer treatment.
- Clinical Trial Support: The combination of VENCLYXTO and acalabrutinib demonstrated superior efficacy over chemoimmunotherapy in the Phase 3 AMPLIFY trial, reducing the risk of disease progression or death by 35%, providing patients with a more effective treatment option.
- Patient Benefits: The new therapy's fixed-duration and chemotherapy-free nature offers the potential for treatment-free intervals, significantly improving patients' quality of life and meeting the evolving needs of patients and healthcare providers for flexible treatment options.
- Market Potential: With VENCLYXTO approved in over 80 countries, AbbVie enhances its competitive edge in the global market through this indication expansion, which is expected to drive future revenue growth for the company.
See More
